Risk factors for gastrointestinal bleeding associated with low-dose aspirin

2012 ◽  
Vol 26 (2) ◽  
pp. 125-140 ◽  
Author(s):  
Vera E. Valkhoff ◽  
Miriam C.J.M. Sturkenboom ◽  
Ernst J. Kuipers
Keyword(s):  
Risk Factors ◽  
Gastrointestinal Bleeding ◽  
Low Dose ◽  
Dose Aspirin ◽  
Low Dose Aspirin

Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin

2000 ◽  
Vol 95 (9) ◽  
pp. 2218-2224 ◽  
Author(s):  
Henrik Toft Sorensen ◽  
Lene Mellemkjaer ◽  
William J. Blot ◽  
Gunnar Lauge Nielsen ◽  
Flemming Hald Steffensen ◽  
...  
Keyword(s):  
Gastrointestinal Bleeding ◽  
Low Dose ◽  
Upper Gastrointestinal Bleeding ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
Upper Gastrointestinal

scholarly journals Effect of Proton Pump Inhibitors on Risks of Upper and Lower Gastrointestinal Bleeding among Users of Low-Dose Aspirin: A Population-Based Observational Study

2020 ◽  
Vol 9 (4) ◽  
pp. 928
Author(s):  
Luis A. García Rodríguez ◽  
Angel Lanas ◽  
Montse Soriano-Gabarró ◽  
Pareen Vora ◽  
Lucía Cea Soriano
Keyword(s):  
Observational Study ◽  
Gastrointestinal Bleeding ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Low Dose ◽  
Population Based ◽  
Lower Gastrointestinal Bleeding ◽  
Aspirin Therapy ◽  
Dose Aspirin ◽  
Low Dose Aspirin

Estimates of the effect of proton pump inhibitors (PPIs) on risks of upper and lower gastrointestinal bleeding (UGIB and LGIB) among low-dose aspirin users in routine clinical practice are variable (UGIB) or lacking (LGIB). We aimed to establish these risks in the same observational study population. Using UK primary care data, we followed 199,049 new users of low-dose aspirin (75–300 mg/day) and matched non-users at start of follow-up to identify incident UGIB/LGIB cases. In nested case–control analyses, adjusted odds ratios (ORs) were calculated for concomitant PPI use vs. past (discontinued) PPI use among current low-dose aspirin users. For UGIB (n = 987), ORs (95% CIs) were 0.69 (0.54–0.88) for >1 month PPI use and 2.65 (1.62–4.3) for ≤1 month PPI use. Among the latter group, ORs (95% CIs) were 3.05 (1.75–5.33) for PPI initiation after start of aspirin therapy, and 1.66 (0.63–4.36) for PPI initiation on/before start of aspirin therapy. For LGIB (n = 1428), ORs (95% CIs) were 0.98 (0.81–1.17) for >1 month PPI use and 1.12 (0.73–1.71) for ≤1 month PPI use. Among low-dose aspirin users, maintaining PPI use (>1 month) was associated with a significantly reduced UGIB risk. Neither short nor long-term PPI use affected LGIB risk.

Sign in / Sign up

Export Citation Format

Share Document